Subscribe for the newsletter
Mobile Navigation
Subscribe for the Newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Metastatic Melanoma
Sort By
Newest First
1 / 1
1 / 1
Sign in
Therapy Approval
KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Merck & Co.
PR-M07-18-NI-098
Jul 30, 2018
